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Abstract
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Traumatic brain injury (TBI) is an international health concern often resulting in chronic
neurological abnormalities, including cognitive deficits, emotional disturbances, and motor
impairments. An anti-CD11d monoclonal antibody that blocks the CD11d/CD18 integrin and
vascular cell adhesion molecule (VCAM)-1 interaction following experimental spinal cord injury
improves functional recovery, while reducing the intraspinal number of neutrophils and
macrophages, oxidative activity, and tissue damage. Since the mechanisms of secondary injury in
the brain and spinal cord are similar, we designed a study to evaluate fully the effects of antiCD11d treatment after a moderate lateral fluid percussion TBI in the rat. Rats were treated at 2 h
after TBI with either the anti-CD11d antibody or an isotype-matched control antibody 1B7, and
both short (24- to 72-h) and long (4-week) recovery periods were examined. The anti-CD11d
integrin treatment reduced neutrophil and macrophage levels in the injured brain, with
concomitant reductions in lipid peroxidation, astrocyte activation, amyloid precursor protein
accumulation, and neuronal loss. The reduced neuroinflammation seen in anti-CD11d-treated rats
correlated with improved performance on a number of behavioral tests. At 24 h, the anti-CD11d
group performed significantly better than the 1B7 controls on several water maze measures of
spatial cognition. At 4 weeks post-injury the anti-CD11d-treated rats had better sensorimotor
function as assessed by the beam task, and reduced anxiety-like behaviors, as evidenced by
elevated-plus maze testing, compared to 1B7 controls. These findings suggest that
neuroinflammation is associated with behavioral deficits after TBI, and that anti-CD11d antibody
treatment is a viable strategy to improve neurological outcomes after TBI.
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Introduction
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Traumatic brain injury (TBI) is an international health concern, often resulting in chronic
neurological abnormalities including cognitive deficits, emotional disturbances, and motor
impairments (Maas et al., 2000; Marshall, 2000; Rao and Lyketsos, 2000). The development
of effective pharmacological interventions for TBI has had only limited success
(Doppenberg et al., 2004; Thompson et al., 2005). This lack of effective treatment is likely
due to the complex pathological processes of primary and secondary injury that follow TBI
(Atif et al., 2009; Morganti-Kossmann et al., 2002; Schmidt et al., 2005). Primary injury
consists of damage induced by the mechanical forces applied to the brain at the time of
impact (Graham et al., 2000; Marshall, 2000). Secondary injury results from processes that
are initiated by the primary insult, such as activation of inflammatory processes that can
induce secondary damage by apoptosis, lipid peroxidation, oxidative stress, or free radical
formation (Bao et al., 2004a, 2004b; Farkas et al., 1998; Hall, 1995; Juurlink and Paterson,
1998; Morganti-Kossmann et al., 2001; Schmidt et al., 2005; Taoka and Okajima, 1998).
The neuroinflammatory response is characterized by the activation of microglia and
astrocytes, the release of proinflammatory cytokines and chemokines, and the migration of
leukocytes across the blood–brain barrier (Ghirnikar et al., 1998; Holmin et al., 1998;
Kadhim et al., 2008; Laird et al., 2008; Morganti-Kossmann et al., 2007). These infiltrating
leukocytes can further exacerbate the inflammatory response and worsen secondary damage
through the production of proinflammatory mediators and free radicals (Juurlink and
Paterson, 1998; Schoettle et al., 1990; Taoka and Okajima, 1998; Zhuang et al., 1993).
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The infiltration of leukocytes into the central nervous system (CNS) is mediated in part by
CD11/CD18 integrins, a family of membrane-bound glycoproteins. The CD11/CD18
heterodimer is composed of a common CD18 (β2) subunit, and one of four CD11 alpha
subunits (a–d). The CD11d/CD18 integrin is expressed on monocytes/macrophages and
neutrophils, and binds to adhesion molecules in both rats (vascular adhesion molecule-1;
VCAM-1), and humans (VCAM-1 and intercellular adhesion molecule; ICAM; Bevilacqua,
1993; Hogg and Leitinger, 2001). In previous work in our laboratory, we used an antiCD11d monoclonal antibody (mAb) to block the CD11d/CD18 and VCAM-1 interaction
following experimental spinal cord injury (SCI) in rats (Bao et al., 2004a, 2004b, 2005; Gris
et al., 2004; Oatway et al., 2005; Saville et al., 2004). These studies revealed that shortlasting treatment with a CD11d mAb for up to 48 h after SCI improves functional recovery,
while reducing the number of neutrophils and macrophages, the formation of reactive free
radicals, lipid peroxidation, protein nitration, and DNA damage (Bao et al., 2004a, 2004b;
Gris et al., 2004; Saville et al., 2004). As these mechanisms also contribute to secondary
injury following TBI, we set out to evaluate the therapeutic potential of the anti-CD11d
treatment following TBI in rats. Herein we report that the anti-CD11d treatment reduces
neutrophil and macrophage infiltration into the injured brain, and consequently reduces lipid
peroxidation, free radical formation, astrocyte activation, amyloid precursor protein (APP)
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expression, and neuronal loss. The neuroprotective effect of the CD11d mAb treatment
correlates with reduced impairment in tests of spatial cognition, anxiety, and sensorimotor
function.
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Methods
Subjects
All procedures and behavioral tests were performed in accordance with the guidelines of the
Canadian Council on Animal Care, and were approved by the University of Western Ontario
Animal Use Subcommittee. The subjects were 114 adult male Long-Evans hooded rats
obtained from Charles River Laboratories (Quebec, Canada). Prior to surgery the rats
weighed between 250 and 300 g, and were naïve to all experimental procedures. After
surgery the rats were housed individually for the remainder of the study under a 12-h light/
dark cycle and were allowed access to food and water ad libitum. Long-Evans rats were
chosen for these studies because they exhibit superior cognitive ability and prolonged
functional impairments following TBI, relative to other rat strains (Tan et al., 2009).
Cognitive deficits and chronic neurological impairments are common in the clinical TBI
setting. The numbers of rats used for each part of the study are outlined in Table 1.
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Treatment groups
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Rats were randomly assigned to one of three treatment conditions: sham-injury with saline
injection (sham), treatment of TBI rats with an isotype-matched control mAb designated
1B7 or with an anti-CD11d mAb. In previous studies using anti-integrin mAb, we have
shown that animals treated with saline have similar outcomes to those treated with an
isotype-matched antibody (Fleming et al., 2008; Gris et al., 2004; Oatway et al., 2005).
Therefore, we elected to include only a saline-treated sham-injury group. The rats received
their assigned treatment (saline, 1B7, or CD11d mAb) at 2 h post-injury via tail vein
injection (1.0 mg/kg). The antibody treatments were in vials marked A or B, and the code
for their identity was established by an investigator who did not participate in the
experiments. Groups of rats undergoing fluid percussion injury (FPI) surgery on a particular
day contained those treated with 1B7 or with the CD11d mAb. Sham-injured rats were
prepared on the same days as TBI rats and had the same survival periods. The rats were
tested on behavioral tasks of spatial cognition, sensorimotor ability, and anxiety-like
behavior. As TBI is associated with acute and chronic changes, both short recovery (SR, 24
h) and long recovery (LR, 4 week) periods were used. The following groups were tested:
anti-CD11d-SR, n = 25; anti-CD11d-LR, n = 14; 1B7 control-SR, n = 24; 1B7 control-LR, n
= 14; sham-SR, n = 24; and sham-LR, n = 14. To provide brain tissue for histological
analysis of leukocyte infiltration after injury (Carlos et al., 1997; Clark et al., 1996;
Donnelly and Popovich, 2008; Utagawa et al., 2008), approximately half of the SR rats were
perfused 24 h post-injury after the completion of elevated-plus maze testing. All other rats
were perfused immediately after the completion of behavioral testing approximately 72 h or
30 days post-injury.
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Fluid percussion brain injury model
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TBI was induced using a standardized fluid percussion injury method as previously
described (Thompson et al., 2005). The fluid percussion force (2.5–3.0 atm) was chosen
based on force values used in previous studies. The rats were placed in a sealed acrylic glass
box into which 4% isoflurane and 2 L/min oxygen flow was introduced for anesthesia.
Under aseptic conditions the rats underwent a craniotomy. All craniotomies were circular
windows (3 mm diameter) centered over the following coordinates with reference to the
bregma: anterior/posterior −3.0 mm; medial/lateral 6.0 mm (Paxinos and Watson, 1986). A
hollow plastic injury cap was sealed over the craniotomy with silicone adhesive and
cyanoacrylate. Three small stainless steel screws were inserted into the skull surrounding the
injury cap to provide anchors for dental acrylic, which attached the injury cap to the skull.
After the dental acrylic hardened the scalp was sutured, the injury cap was filled with sterile
saline, and the rat was attached to the FPI device. At the first response of hindlimb
withdrawal to a toe pinch, the rats in the anti-CD11d or 1B7 control groups received a single
fluid percussion pulse of 2.5–3.0 atm. Sham-injured rats had the same craniotomy and injury
cap but were removed from the FPI device without receiving fluid percussion (Thompson et
al., 2005).
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Apnea, tune of unconsciousness, and self-righting reflex were monitored immediately
following injury. Apnea times were determined as the time from injury to the return of
spontaneous breathing. Time of unconsciousness was determined by the return of hindlimb
withdrawal in response to toe pinch. Self-righting was determined as the time from injury to
return to an upright position from lying on the side. As shown in Table 2, CD11d- and 1B7mAb-treated TBI rats displayed significantly longer periods of apnea, unconsciousness, and
self-righting reflex times than sham-injured rats. Four rats died as a result of FPI and one rat
lost its injury cap prior to the start of behavioral testing and was removed from the study.
After these immediate post-injury tests were completed all rats received a subcutaneous
injection of analgesic (ketoprofen, 5 mg/kg). Two hours post-injury, the rats received tail
vein injections of their assigned treatment or saline. Behavioral testing began after each
group’s recovery time was complete.
Tissue preparation for histochemical and biochemical analyses
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For histological examination at 24 h, 72 h, and 4 weeks after injury, the animals were
anesthetized (2.5 g/kg urethane), and perfused transcardially with saline, followed by 4%
paraformaldehyde in phosphate-buffered saline (PBS; pH 7.2–7.4). The brains were
removed, post-fixed for 24 h at 4°C, cryoprotected in increasing concentrations of sucrose,
and sectioned into 35-μm sections for immunohistochemical staining. The entire brain was
sectioned coronally and floating sections containing a visible hippocampus (approximately 3
mm caudal to the bregma) were saved for immunohistochemical staining. Approximately 10
of these sections were mounted on slides for hematoxylin and eosin staining. For
biochemical assays and Western blotting, animals at 24 h, 72 h, and 4 weeks post-injury
were perfused with cold 0.9% NaCl and their were brains removed. The brainstem and
cerebellum were removed and the injured half of the remaining brain was bisected and
subsequently homogenized and stored at −80°C.
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Immunohistochemistry and histology
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Monoclonal mouse antibodies: anti-ED1 (1:500; Serotec, Raleigh, NC), anti-NeuN (1:500,
Chemicon, Temecula, CA), anti-glial fibrillary acidic protein (GFAP, 1:500; Sigma-Aldrich,
St. Louis, MO), and polyclonal rabbit anti-rat antibodies against amyloid precursor protein
(APP, 1:200; Sigma-Aidrich) and against a 56kDa neutrophil protein (1:20,000, a gift of Dr.
Daniel Anthony, Oxford University, Oxford, U.K.) were used for immunohistochemical
staining. Representative sections (at least 3 per animal) of the injured area from each animal
were processed free-floating for staining as described previously (Bao et al., 2005).
Immunoreactivity was revealed with a glucose-diaminobenzidine-nickel solution. Fields of
view were captured digitally by a Retiga 1300 videocamera (Quantitative Imaging
Corporation, Burnaby, BC), and ImagePro Plus Software (Media Cybernetics, Silver Spring,
MD). For quantification of the inflammatory infiltrates, photomicrographs were captured
from coronal sections deemed by inspection of the tissue structure to be close to the level of
injury (approximately −3.0 mm to the bregma). Using Image Pro Plus software the color
threshold was adjusted to detect immunostained inflammatory cells, and the number of
colored objects was counted within a 0.2-mm2 area of interest centered on the lesion
epicenter at a depth that included the area of greatest immunoreactivity. Neurons
immunoreactive for neuronal nuclear antigen (NeuN) were counted in the hippocampus at 4
weeks post-injury as an indication of neuronal survival levels (D’Avila et al., 2012). For this
analysis, a 20× field of view (0.33 mm2 in area) was sampled using the hippocampal shape
as the landmark. The selected field included the end of CA2 and beginning of CA3, ~3 mm
caudal to the bregma. Cells were counted visually and an average number over three sections
was calculated for each animal. Because sections were sampled from a group of floating
sections, stereological methods for counting were not used.
Western blotting analysis
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Tissue sample preparation and protein determination were performed as described
previously (Bao et al., 2004b). Primary antibodies used included: anti-ED1 (1:1000;
Serotec), anti-GFAP (1:5000; Sigma-Aldrich), anti-App (1:2000; Sigma-Aldrich) antineutrophil (1:20,000, a gift of Dr. Daniel Anthony, Oxford University, Oxford, U.K.), antiNeuN (1:5000; Chemicon), and anti-β-actin (1:10,000; Sigma-Aldrich). Signal detection
was facilitated with enhanced chemiluminescence (ECL kit; Amersham, Piscataway, NJ).
Immunoreactive bands were scanned by an imaging densitometer (BioRad GS-700 Imaging
Densitometer), and the results were quantified using Multi-Analyst software (Bio-Rad).
Densitometric values were normalized for protein loading using β-actin as a loading control.
MPO assay—MPO enzymatic activity is derived mostly from neutrophils and to a lesser
extent from macrophages. This activity, an estimate of the extent of neutrophil infiltration/
activation and macrophage activation, was measured as described previously (Bao et al.,
2004b). MPO activity was calculated using a standard curve prepared with purified human
MPO (Sigma-Aldrich). Results are expressed as units per milligram of protein.
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Measurement of lipid peroxidation
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The relative levels of aldehydes, including malondialdehyde (MDA), indicators of lipid
peroxidation, were measured using the thiobarbituric acid reactive substances (TBARS)
assay, as previously described (Ohkawa et al., 1979). MDA bis (dimethyl acetal; SigmaAldrich) was used as a standard, and the level of lipid peroxide was expressed as nanomoles
of TBARS/mg protein.
Behavioral tests day 1
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Elevated-plus maze. Behavioral testing was performed as previously described (Shultz et al.,
2011a). Day 1 testing began 24 h after TBI for SR rats, or 28 days after TBI for LR rats.
First, anxiety-associated behavior was assessed using the elevated-plus maze, consisting of
two closed arms (arms enclosed by 18-inch-high walls), and two open arms (arms not
enclosed by walls). The rats were allowed to explore the maze freely for 5 min. Following
testing, a videotape of the trial was scored by a person blind to treatment group, and the
number of entries into, and the amount of time spent in, each arm were recorded. Time spent
in the open arm was decreased in rats with more anxiety-related behaviors. Accordingly, a
percentage score was calculated for the time spent in the open arm: time in open arm/[time
in open arm + time in closed arm] (Saucier et al., 2008; Shultz et al., 2011b; Steimer and
Driscoll, 2003; Zhu et al., 2006). The number of entries into the closed arm of the maze was
also calculated as a measure of locomotion. Half of the SR rats were sacrificed following the
elevated-plus maze testing for analysis at 24 h post-injury.
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Water maze—Next, spatial cognition was assessed using a circular water maze. A clear
acrylic glass escape platform was hidden 2 cm below the water’s surface in the center of the
southeast quadrant of the pool. Polypropylene beads floating on the water prevented the rats
from seeing the hidden platform (Cain and Boughey, 1993). Acquisition training began
immediately following elevated-plus maze testing and consisted of 10 training trials. A trial
began by placing the rat in the pool adjacent to and facing the pool wall, and ended when the
rat stood on the hidden platform. Each trial began at one of four pool wall start locations
(north, south, east, or west) according to a pseudo-random schedule of start locations that
prevented repeated sequential starts from the same location. As the four start locations
varied in distance from the hidden platform, the time to reach the platform was averaged for
every block of two trials [e.g., block 1 = (trial 1 + trial 2)/2]. Behavior was analyzed by a
tracking system that digitized each swim trial (Poly-Track; San Diego Instruments, San
Diego, CA). The tracking system also permitted analysis of the percentage of time the rats
swam directly toward the platform or swam around it. Search time and direct and circle
swims were used as measures of spatial place memory (Morris, 1989; Whishaw and Jarrard,
1995). Swim speed was used as a measure of motor ability and was objectively calculated in
centimeters per second by the Poly-Track system.
Beam task—Finally, training was done on a beam task that assesses sensorimotor function
(Kolb and Whishaw, 1985). One edge of the beam was 4 cm wide and the other edge was 2
cm wide. For acclimation to the beam task, the rats were given a training session consisting
of five trials to traverse the beam with the 4cm edge facing up, and another five trials with
the 2-cm edge of the beam facing up.
J Neurotrauma. Author manuscript; available in PMC 2016 May 03.
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Behavioral tests day 2
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Testing on day 2 began 48 h after TBI for SR rats or 29 days after TBI for LR rats. The
beam test session began approximately 24 h after the beam training session and consisted of
10 trials. A trial was begun by placing a rat at one end of the beam and ended when the
animal successfully reached the goal platform. A maximum of 60 sec was allowed for each
trial. Traverse time and the number of slips and falls were used as measures of sensorimotor
function.
Immediately following beam testing, the rats underwent a second water maze session for
reversal training. The reversal test is a more challenging cognitive test, as it assesses the
capacity of the rats to disregard what they had learned in the previous trial and to learn a new
location for the escape platform. The procedures for the reversal session were identical to
acquisition except that the hidden platform was now located in the opposite quadrant of the
pool relative to the location during acquisition.
Statistical analysis
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Histochemical and biochemical results were analyzed using a completely randomized oneway analysis of variance (ANOVA). Differences between means were determined by the
post-hoc Student Neuman Keuls test. These analyses were done using SigmaStat (Systat
Software, San Jose, CA). Water maze search time and beam traverse time were analyzed
using repeated-measures ANOVA with injury as the between-subjects factor and trial as the
within-subjects factor. One-way ANOVA, with injury as the between-subjects factor, was
used to analyze the percent of time in the open arm, closed arm entries, direct and circle
swims, swim speed, and slips and falls. Fisher’s LSD post-hoc pair-wise comparisons were
carried out when appropriate. These analyses were done using SPSS 17.0 (IBM, Armonk,
NY). Mean values in all comparisons are expressed ± standard error (SE). Significance in all
analyses was accepted at p ≤ 0.05. Values of p presented in the results refer to the post-hoc
tests. Details of the ANOVA are presented in the figure legends, with the exception of water
maze search time and beam traverse time, which are given in the results section.

Results
CIHR Author Manuscript

Histochemical and biochemical findings at 24 h, 72 h, and 4 weeks after TBI
Sections from sham-injured, 1B7-, and CD11d mAb-treated rats were stained with
hematoxylin and eosin 24 h after injury or sham surgery to examine their acute pathological
changes. Sections from the sham-injured rats revealed normal brain parenchyma both at the
cortical surface and in the deeper layers including the hippocampal gyrus (Fig. 1A and D).
In contrast, sections from 1B7-treated controls (Fig. 1B and E), and from CD11d-treated rats
(Fig. 1C and F), demonstrated increased cellularity in the cortex, and marked hemorrhage
and tissue disruption in the deeper layers immediately above the hippocampus. Cells with
morphology typical of neutrophils could be detected adjacent to the areas of hemorrhage.
Leukocyte infiltration
We assessed the effect of the anti-CD11d treatment on neutrophil infiltration into the injured
brain at 24 h post-FPI by immunostaining brain sections with an antibody to a 56-kDa
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protein expressed by rat neutrophils. Whereas sections from the sham-injured brains
demonstrated only a few neutrophils (confined to blood vessels) at 24 h after TBI (Fig. 2A,
panels 1 and 4), many neutrophils were detected near the TBI injury site in the parenchyma
of the cortex in 1B7 control rats (Fig. 2A, panels 2 and 5). After anti-CD11d treatment, the
density of these cells appeared to be reduced (Fig. 2A, panels 3 and 6). Counts of
immunostained neutrophils in a 0.2-mm2 area of interest centered on the lesion epicenter in
sections from sham, 1B7, and CD11d mAb-treated rats 24 h after injury demonstrated
significant increases in the numbers of neutrophils in 1B7 control FPI rats compared to the
sham-injured group (Fig. 2B; p < 0.01), no significant increase in the anti-CD11d group, and
significantly fewer neutrophils in the anti-CD11d group than in the 1B7 group (p < 0.05).
The presence of neutrophils in the brain was also quantified using the anti-rat neutrophil
antibody in a Western blot analysis. Neutrophil protein (56 kDa) expression was low in
homogenates from sham-injured rats at 24 and 72 h after TBI (Fig. 2C), but was increased
significantly at 24 h (sevenfold, p < 0.001), and 72 h (~ fivefold, p < 0.001) after injury.
Treatment with the anti-CD11d antibody significantly reduced neutrophil protein levels by
51% (p < 0.01) at 24 h, and by 43% (p < 0.01) at 72 h after injury. At 4 weeks after TBI, the
56-kDa neutrophil protein expression did not differ among the three groups.
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The effect of the anti-CD11d treatment was also assessed on MPO enzymatic activity, a
measure of neutrophil infiltration/activation, and to a lesser degree of macrophage activation.
MPO was minimal in the brains of sham-injured rats at 24 h, 72 h, and 4 weeks after TBI
(Fig. 2B, right). At 24 and 72 h after TBI, MPO activity in the brain homogenates of the 1B7
controls increased significantly (by eightfold at 24 h, by threefold at 72 h; p < 0.001)
compared to the sham-injured rats. The anti-CD11d treatment reduced MPO activity by 54%
and 42%, respectively, from that in the 1B7-treated controls (p < 0.01 for both time points).
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The effect of the anti-CD11d treatment on monocyte/microglia/macrophage populations in
the brain lesions was assessed by quantifying ED-1 (CD11b) immunoreactivity at 72 h and 4
weeks after TBI. In the brains of sham-injured rats, only a few ED-1 immunoreactive (Ir)
cells were present (Fig. 3A, panels 1 and 4). At 72 h and 4 weeks after injury, the density of
ED-1-Ir cells was clearly increased in the 1B7 control rats (Fig. 3A, panels 2 and 5). These
cells had the rounded morphology typical of macrophages and activated microglia, and they
were distributed from the superficial cortical layers through to the deeper layers. After
CD11d antibody treatment, the density of the ED-1-Ir macrophages was clearly reduced
(Fig. 3A, panels 3 and 6). The number of ED-1-Ir macrophages was counted in each of the
three groups at 72 h and 4 weeks after TBI (Fig. 3C). The number of macrophages in the
1B7 controls were increased compared to the number in sham-injured rats by 6.6-fold (p <
0.001) at 72 h, and 15-fold at 4 weeks (p < 0.01) post-injury. Anti-CD11d treatment reduced
these increases by 65% and 54%, respectively (p < 0.001; p = 0.05).
Macrophage levels were also quantified using Western blot analysis for ED-1 (Fig 3C and
D). ED-1 expression (110-kDa band) was low in the brain homogenates of sham-injured
rats, but was increased significantly after TBI at 24 h (3.5-fold, p < 0.01), 72 h (5.3-fold, p <
0.001), and 4 weeks (4-fold, p < 0.001). Treatment with the anti-CD11d antibody
significantly reduced these increases by 46%, 39%, and 30%, respectively (p < 0.05 for all
time points).
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Lipid peroxidation
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An indication of lipid peroxidation that could be due to free radical tissue damage and/or to
activation of the arachidonic acid cascade was evaluated by a TBARS assay that measures
the relative levels of MDA and other aldehydes in tissue homogenates (Fig. 4). After injury
in the 1B7 controls, TBARS concentrations were increased significantly compared to shaminjured rats, by 59%, 72%, and 56%, respectively (p < 0.05 for all time points). After the
anti-CD11d treatment, TBARS in the groups at 24 h, 72 h, and 4 weeks was significantly
reduced compared to the 1B7 controls, by 28%, 27%, and 26%, respectively (p < 0.05 for all
time points), and these values were no different from those in sham-injured rats.
Glial fibrillary acidic protein
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The effect of the anti-CD11d treatment on astrocyte activation in the brain lesions of shaminjured rats, 1B7 mAb-treated controls, and CD11d mAb-treated rats was assessed by
examining GFAP levels by Western blot analysis (Fig. 5A). GFAP (~50 kDa) expression
increased significantly, by ~3-fold in the 1B7 control rats at 24 h, 72 h and 4 weeks after
TBI compared to sham-injured rats (p < 0.001 for all time points). The anti-CD11d
treatment significantly dampened the injury-induced increase in GFAP expression (seen in
the 1B7 controls) by 37% at 24 h (p < 0.001), by 41% at 72 h (p < 0.01), and by 37% at 4
weeks (p ≤ 0.01) after TBI. Immunohistochemistry using the GFAP antibody on sections
from injured brains 4 weeks post-injury demonstrated increased astrogliosis, with denselystained astrocytes bearing long, overlapping hypertrophic processes in the brains of the 1B7
mAb-treated controls (Fig. 5B, panels 2 and 5), compared to similar sections from CD11d
mAb-treated or sham-injured control rats (Fig. 5B, panels 1, 3, 4, and 6). The same pattern
of glial activation and treatment effect of the anti-CD11d antibody was observed in brain
sections from rats examined at 24 h and 72 h after TBI (data not shown).
Amyloid precursor protein (APP)

CIHR Author Manuscript

APP expression has been shown to increase after neuronal injury due to TBI (Itoh et al.,
2009; Murakami et al., 1998; Otsuka et al., 1991). The effect of the anti-CD11d treatment on
neuronal damage was assessed in homogenates of the rat brains using Western blot analysis
(Fig. 6A). Expression of APP (90 kDa) was evident in the brains of all sham-injured rats.
This expression increased significantly after TBI in the 1B7 control rats at 24 h (by 3-fold, p
< 0.01), at 72 h (by 3.4-fold, p < 0.001), and 4 weeks (by 4.4-fold, p < 0.01). The antiCD11d treatment significantly reduced the injury-induced increase in APP expression (from
the 1B7 control values), by 32% at 24 h (p < 0.05), by 31% at 72 h (p < 0.05), and by 39% at
4 weeks (p = 0.050) after TBI. Immunohistochemistry demonstrated low levels of APP
expression in small punctate areas of the cortex in the sham-injured rats at 4 weeks after
injury (Fig. 6B, panels 1 and 4). In contrast, large dark patches of APP immunoreactivity
were present in the cortical areas adjacent to the lesions in 1B7 control rats at 4 weeks after
the injury (Fig. 6B, panels 2 and 5). APP expression in the brains of anti-CD11d-treated rats
at this time appeared less intense, and the patches of immunoreactivity were smaller than in
the 1B7 controls (Fig. 6B, panels 3 and 6). A similar pattern of APP expression and effect in
sham-injured, 1B7, and anti-CD11d-treated rats was observed at 24 h and 72 h after TBI
(data not shown).
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Neuronal survival
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To provide a general estimate of neuronal survival after TBI, Western blotting for the
neuronal marker NeuN was done using the brain homogenates. Robust expression of this
protein was evident in all of the brains sampled (Fig. 7). Densitometry demonstrated that
compared to sham-injured rats, expression of the NeuN protein decreased significantly in
1B7 control rats at 24 h (by 47%, p < 0.01), at 72 h (by 61%, p < 0.001), and at 4 weeks (by
67%, p < 0.001). The decreases in NeuN expression (from the sham-injured group) were
smaller after anti-CD11d treatment (by 23%, 29%, and 38%, respectively), and all were
significantly different from those in the 1B7 control group (p < 0.05, p < 0.01, and p = 0.05,
respectively).
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Because of the apparent tissue damage seen near the hippocampus in the hematoxylin and
eosin-stained sections at 24 h after TBI (Fig. 1), and evidence from others that the
hippocampus is particularly vulnerable to injury following lateral FPI (Grady et al., 2003),
we evaluated the hippocampus as a site in which changes in neuron numbers might be
detected by immunohistochemistry after TBI. At 4 weeks after TBI, the density of neurons
distributed in the CA2-CA3 region of the hippocampus appeared decreased in the tissue
sections of 1B7 control rats compared to the sham-injured and CD11d-mAb-treated rats
(Fig. 8A). Although differences between the 1B7 group and the anti-CD11d group
sometimes were not obvious from casual inspection, counts of the hippocampal neurons at 4
weeks after TBI revealed a significant increase (~ 20%) in the number of NeuN-expressing
cells within a defined area of interest in the CA2-CA3 region in anti-CD11d-treated rats
compared to the 1B7 control group (Fig. 8B, p<0.05). No differences in hippocampal
neuronal counts were detected among the groups at 24 h or 72 h after TBI.
Behavioral findings: Water maze
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To assess the effects of the anti-CD11d treatment on spatial cognition we analyzed
acquisition time and the percentage of direct and circle swims in sham, 1B7, and CD11d
mAb-treated rats. At 24 h post-injury, acquisition search time decreased in all groups as
testing progressed, as indicated by a significant effect of trial (Fig. 9A; F9,306=5.473,
p<0.001). However, search time decreased less in the 1B7 control and anti-CD11d groups
than in the sham-injured group, as indicated by a significant effect of treatment (F2,34 =
7.655, p<0.01; 1B7 control and anti-CD11d >sham, p<0.05). In addition, a non-significant
trend was noted for 1B7 control rats to display longer search times than anti-CD11d rats
(p<0.10). The direct and circle swim data were consistent with the search time data in
revealing fewer direct and circle swims in the 1B7 control group during acquisition
compared to sham-injured rats (Fig. 9B, p<0.01). Anti-CD11d rats tended to display fewer
direct and circle swims than sham-injured rats (p<0.10). Swim speed did not differ among
the three groups (Fig. 9C).
During reversal training 48 h post-injury, search time decreased in all groups as testing
progressed, as indicated by a significant effect of trial (Fig. 9D; F9,306=4.330, p<0.001).
However, search times decreased more in the anti-CD11d and sham-injured groups than in
the 1B7 control group, as indicated by a significant effect of treatment (F2,34 = 7.912,
p<0.001; 1B7 control > sham-injured and anti-CD11d rats; p < 0.01). The direct and circle
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swim data were consistent with the search time data in revealing more direct and circle
swims in the anti-CD11d and sham-injured groups than in the 1B7 control group (Fig. 9E;
p<0.05). Again swim speed did not differ among the treatment groups (Fig. 9F).
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At 4 weeks post-injury search times during acquisition training did not differ between
groups (Fig. 10A). However, whereas the anti-CD11d treated rats did not differ significantly
from sham-injured rats, the 1B7 control rats displayed fewer direct and circle swims than
sham-injured rats (Fig. 10B; p <0.01). In addition, the 1B7 control rats tended to display
fewer direct and circle swims than anti-CD11d rats (p <0.10). Swim speed did not differ
among groups during the 4-week acquisition training (Fig. 10C). Furthermore, the groups
demonstrated no significant differences in search time, direct and circle swims, or swim
speed during reversal training.
Behavioral findings: Beam task
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Sensorimotor testing on the beam task at 48 h after injury demonstrated that the 1B7 control
group executed more slips and falls than the sham-injured group (Fig. 11A; p<0.01). In
contrast, the anti-CD11d treatment group did not differ from the sham-injured group. No
significant group differences in beam traverse times were detected (p > 0.05; data not
shown). During beam testing 4 weeks post-injury the anti-CD11d and sham-injured groups
displayed fewer slips and falls than the 1B7 control group (Fig. 11B; p<0.05). No significant
group differences in beam traverse times were found (p>0.05; data not shown).
Behavioral findings: Elevated-plus maze
At 24 h post-injury, no differences were found in the percent of time spent in the open arm
or number of closed arm entries (Fig. 12A and B; p>0.05). However, testing at 4 weeks postinjury demonstrated that the anti-CD11d and sham-injured groups spent a greater proportion
of time in the open arms compared to the 1B7 control group (Fig. 12C; p<0.05). The number
of closed arm entries did not differ between groups (Fig. 12D).

Discussion
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The analysis of neutrophils and macrophages in the injured brains revealed a significant
reduction in their levels in rats treated with the CD11d mAb. The reduced inflammatory
response after TBI was paralleled by decreases in MPO levels, lipid peroxidation,
astrogliosis, axonal injury, and neuronal loss in the brains of anti-CD11d-treated rats. The
behavioral studies demonstrated that anti-CD11d integrin antibody treatment also reduced
cognitive impairment, anxiety-like behaviors, and sensorimotor loss, relative to treatment
with a control antibody after TBI. These robust changes were accomplished by a single
intravenous treatment with the CD11d mAb. The anti-inflammatory effects of this treatment
clearly lasted up to 72 h after the injury. This acute modification of the inflammatory cell
population within the injured brain had long-lasting effects on the 4-week behavioral
outcomes, as well as normalizing the glial and neuronal population responses at this time.
Our data also confirm a preliminary study that demonstrated reduced contusion volume and
macrophage infiltration in CD11d mAb-treated rats after TBI (Utagawa et al., 2008). Despite
the reduction of the macrophage population in the injured brains in our CD11d mAb-treated

J Neurotrauma. Author manuscript; available in PMC 2016 May 03.

Bao et al.

Page 12

CIHR Author Manuscript

animals, they had no infections in the CNS or elsewhere. This likely reflects the fact that the
treatment was completed 48h post-injury, thus limiting the window of time during which the
animals might be vulnerable to infection due to CD11d antibody-compromised leukocyte
trafficking. These results are also similar to the functional improvements and reductions in
inflammation demonstrated using acute administration of an ICAM-1 antibody (ICAM-1 is
the receptor on endothelial cells that binds CD11d/CD18), and a P-selectin antibody (Pselectin also mediates neutrophil adhesion to endothelial cells) after FPI in rats (Grady et al.,
1999; Knoblach and Faden, 2002).
Neuroinflammation and oxidative injury
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The reduced neutrophil and macrophage populations in the injured brain after anti-CD11d
treatment decreased the neuronal loss and axonal damage caused by the FPI, as the 1B7
control rats had significantly more of this loss than the anti-CD11d-treated group. The
neutrophil influx was key to the intensity of the inflammation, as many of the macrophages
likely originated from microglial activation initiated in part by the presence of the
neutrophils (David and Kroner, 2011). The neurotoxic actions of inflammation within the
brain are known to contribute to secondary damage after TBI (Dringen, 2005; MorgantiKossmann et al., 2001; Schmidt et al., 2005). It follows that neuroinflammation and
neuronal injury and loss could have contributed to the behavioral impairments induced by
lateral FPI in the current study. The oxidative burst of activated neutrophils and
macrophages generates free radicals that can lead to secondary CNS injury (Juurlink and
Paterson, 1998; Lewen et al., 2000). Free radicals can induce tissue damage in the form of
peroxidation of lipid membranes, protein nitration, and nucleic acid damage (Leski et al.,
2001), all of which critically alter cellular function. The enzyme MPO is part of the pathway
that generates oxidative stress via formation of hydrogen peroxide and other oxidative
molecules. MPO is present in large quantities in granules within neutrophils, and in lesser
quantities in macrophages (Barone et al., 1991; Bradley et al., 1982). At 24 h and 72 h postinjury, the anti-CD11d mAb treatment reduced MPO levels in the injured brain. Downstream
lipid peroxidation in the injured brain was also significantly reduced by the anti-CD11d
treatment.
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The inflammatory response leads to a variety of cellular reactions within the injured brain.
Astrogliosis was readily detected in rat brains after FPI by the intense increase in expression
of GFAP that lasted for at least 4 weeks. Astrogliosis is both a marker of neuropathology
and an active participant in neuroinflammation (Hamby and Sofroniew, 2010). Astrocytes
respond to a host of cytokines that may be released by activated neutrophils and
macrophages, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-1b, and
may in turn release the same as well additional cytokines that regulate nearby microglia,
neurons, and other astrocytes (Sofroniew, 2009). Thus the reduced astrogliosis in antiCD11d-treated rats may be a reflection of, and may help maintain, the reduced
neuroinflammation.
Expression of APP has been shown to increase after TBI, and is associated with axonal
damage (Itoh et al., 2009; Murakami et al., 1998; Otsuka et al., 1991). Accumulations of
APP were found in the injured cortex, and Western blots quantified increased APP
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expression as early as 24 h after injury. Increased expression of APP was maintained for the
4-week duration of our study. The anti-CD11d treatment reduced the increase in APP
expression compared to 1B7 mAb-treated controls, but the APP in CD11d mAb-treated rats
remained greater than in sham-injured rats, perhaps indicating that the reduction in
inflammation reduced, but did not completely prevent, inflammatory-mediated axonal
injury.
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The secondary neuronal loss, due in part to inflammation, was monitored by Western blot
analysis for NeuN levels, and by counting NeuN-expressing cells in the hippocampus. The
Western blot analysis of brain homogenates revealed a significant reduction in NeuN
expression at 24 h, 72 h, and 4 weeks after injury in 1B7 controls compared to sham-injured
rats. Whereas NeuN expression levels were also lower in CD11d mAb-treated rats compared
to sham-injured rats at these time points, NeuN expression was still significantly greater in
the anti-CD11d-treated rats compared to the 1B7 controls at all time points tested. Cell
counts in the CA2-CA3 regions of the hippocampus revealed a significant reduction (22%)
in the number of NeuN-expressing cells in 1B7 controls compared to sham-injured rats at 4
weeks, but not at the earlier time points. The anti-CD11d treatment prevented this loss of
hippocampal neurons, a likely mechanism for some of the behavioral recovery associated
with the treatment (see further discussion below). The Western blot analysis of NeuN
expression showed more differences between groups earlier (at 24 and 72 h) than the cell
counts in the hippocampus, likely indicating that neuronal loss is occurring outside of the
hippocampus, and/or that neurons may reduce NeuN expression without subsequently dying.
Behavioral outcomes
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Previous research from our laboratory and others revealed cognitive deficits in the water
maze in the presence of a neuroinflammatory response (Aiguo et al., 2010; Shultz et al.,
2009; Wu et al., 2006). Other lateral FPI studies have also found motor, emotional, and
cognitive impairments that occurred in the presence of extensive damage to the hippocampus
and the frontal, parietal, and temporal cortices (Jones et al., 2008; Wahl et al., 2000).
Accordingly, damage to the hippocampus and other areas may have contributed to the
behavioral impairments seen in the elevated-plus maze, water maze, and beam task in the
1B7 controls. The CD11d treatment after FPI reduced neuronal loss in the hippocampus and
more generally in the injured hemisphere, an effect that likely accounts for the reduced
behavioral impairments seen in this group.
Short-term cognitive impairments were present in lateral FPI rats at 24 h after injury,
regardless of treatment, as both the anti-CD11d and 1B7 control groups displayed longer
search times than sham-injured rats during water maze acquisition. However, during water
maze reversal, the anti-CD11d group performed as well as the sham-injured group, spending
less time searching for the platform and displaying more direct and circle swims than 1B7
control rats. In addition, by 4 weeks after injury, the anti-CD11d rats displayed no water
maze impairments, whereas the 1B7 control rats had cognitive deficits, indicated by
significantly fewer direct and circle swims during acquisition than the sham-injured rats.
Accordingly, rats treated with anti-CD11d antibody were cognitively impaired only during
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water maze acquisition at 24 h after the TBI, whereas rats treated with the 1B7 control
antibody were cognitively impaired at 24 h and at the late 4-week recovery time point.
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The fine motor deficits on the beam task experienced by the 1B7 control rats suggest that
locomotor ability may need to be considered when interpreting water maze results. However,
swim speed, a direct measure of motor ability in the water maze, did not differ among the
groups, and the 1B7 mAb-treated rats did not demonstrate difficulty in swimming or
climbing onto the hidden platform. Thus the fine motor impairments experienced by the 1B7
group were unlikely to have accounted directly for the deficits observed in the water maze.
At 24 h and 4 weeks post-injury the anti-CD11d-treated rats performed as well as the shaminjured groups on the beam task, and at 4 weeks post-injury the anti-CD11d-treated rats
performed significantly better than the 1B7 mAb-treated rats. The 1B7 mAb-treated rats
displayed significantly more slips and falls than the sham-injured groups at both 24 h and 4
weeks post-injury. These results suggest that the anti-CD11d antibody treatment preserved
motor function following lateral FPI. As the 1B7 mAb-control rats showed no impairments
on the measures of beam traverse time, swim speed, or closed arm entries in the elevatedplus maze, we suggest that their beam task impairments were a result of fine motor deficits
rather than gross motor impairments (Shultz et al., 2009).
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Previous studies have shown that decreased time spent in the open arm of the elevated-plus
maze represents an increase in anxiety-like behavior (Jones et al., 2008; Walf and Frye,
2007). The 1B7 control rats spent less time in the open arm of the elevated-plus maze
compared to both the sham-injured rats and CD11d mAb-treated rats at 4 weeks after the
TBI, suggesting that these rats experienced heightened levels of anxiety, and that the CD11d
treatment reduced the anxiogenic effect of lateral FPI. As locomotor impairments might
confound elevated-plus maze results, the finding that 1B7 control rats displayed impairments
on the beam task must be considered in the interpretation of elevated-plus maze findings.
Although 1B7 control rats displayed increased slips and falls on the beam task, they were
not impaired on the measures of beam traverse time, the number of closed arm entries in the
elevated-plus maze, or swim speed in the water maze. Therefore, 1B7 rats likely experienced
fine motor deficits, or possibly impairments of balance mechanisms, but not gross locomotor
impairment that would confound elevated-plus maze findings. Although the CD11d mAbtreated rats demonstrated better behavioral recovery than the 1B7 controls, they still
performed significantly worse than sham-injured controls on some behavioral measures, and
displayed some neuronal loss. Irreversible primary injuries may have contributed to these
findings (Graham et al., 2000; Marshall, 2000). Moreover, the anti-CD11d treatment reduced
but did not completely prevent the neutrophil and macrophage infiltration of the injured
brain, leading to an attenuated inflammatory response that may have led to the impaired
behavior. As the current study is only the second to use the CD11d mAb to treat TBI, the
treatment regimen applied may not have been optimal, generating a less robust outcome than
may otherwise be possible.

Conclusions
A single treatment of anti-CD11d integrin antibody administered 2h after moderate TBI
reduced cognitive, emotional, and motor impairments in the Long-Evans rat. As the
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reduction in impairment occurred in parallel with decreased neuroinflammation, oxidative
injury, and gross neuronal loss, the anti-CD11d antibody treatment may have improved
outcomes by limiting the infiltration of peripheral leukocytes and decreasing the neurotoxic
effects of neuroinflammation. Together, these findings suggest that infiltrating leukocytes
increase neuroinflammation, secondary brain damage, and functional impairment following
TBI, and that the anti-CD11d antibody holds promise as a novel treatment to limit secondary
injury processes and improve recovery from TBI.
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FIG. 1.

Histological sections of injured brain stained with hematoxylin and eosin 24 h after fluid
percussion injury (FPI). The section is at the location of the FPI and includes the
hippocampus. Areas boxed in low-power photomicrographs (A–C) are shown at high-power
in panels D–F. Sections from the 1B7 control rat and the anti-CD11d-treated rat show areas
of tissue disruption and hemorrhage immediately above and including the hippocampus
(arrowheads; scale bar in A–C = 200 μm; scale bar in D–F = 100 μm).
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FIG. 2.
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Neutrophil infiltration into the injured brain is reduced by the anti-CD11d treatment. (A)
Photomicrographs of the cortex centered on the lesion epicenter (or a comparable position in
sham-injured rats), immunostained by an anti-neutrophil antibody. The sections from shaminjured, 1B7 control, and anti-CD11d-treated rats are shown at low power in panels 1–3,
respectively, and the boxed areas are shown at high power in panels 4–6 (scale bar in A1–3 =
100 μm, and in A4–6 = 100 μm). (B) Left panel shows counts of neutrophils within a 0.2mm2 area of interest centered on the epicenter in the injured brain in the sham, 1B7 control,
and anti-CD11d-treated groups (n = 4/group) at 24 h after injury (*significantly different
from sham animals, and #significantly different from the 1B7 control group, p ≤ 0.05 after
the Student Neuman Keuls test and one-way analysis of variance [ANOVA]; ANOVA for
neutrophil count: F2,9 = 8.6, p = 0.008). (B) Right panels show myeloperoxidase (MPO)
activity in brain homogenates after traumatic brain injury (TBI) at 24 h in sham-injured
animals (n = 6), 1B7 controls, and anti-CD11d animals (n = 7/group); at 72 h in these groups
(n = 7, 8, and 7, respectively); and at 4 weeks (n = 5, 6, and 5, respectively; ANOVA: 24 h,
F2,17 = 13.63, p < 0.001; 72 h, F2,19 = 11.75, p < 0.001; 4 weeks, F2,13 = 2.74, p = 0.102).
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(C) Neutrophil protein identified by Western blotting in brain homogenates expressed as
means ± standard error with a representative autoradiogram shown above each set of
histograms. Neutrophil protein is shown at 24 h, 72 h, and 4 weeks in sham-injured, 1B7
controls, and anti-CD11d groups (n = 5/group; ANOVA: 24 h, F2,12 = 20.52, p < 0.001; 72
h, F2,12 = 20.70, p < 0.001; 4 weeks, F2,12 = 2.92, p = 0.09; A.U., arbitrary units). Color
image is available online at www.liebertonline.com/neu
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FIG. 3.

Macrophages in the injured brain are reduced by the anti-CD11d treatment. (A and B)
Photomicrographs 72 h or 4 weeks post-injury of the cortex centered on the lesion epicenter
(or a comparable position in sham-injured rats), immunostained by an anti-ED-1 antibody.
The sections from sham-injured, 1B7 control, and anti-CD11d-treated rats are shown at low
power in panels 1–3, respectively, and the boxed areas are shown at high power in panels 4–
6 (*significantly different from sham animals, and #significantly different from the 1B7
control group, p ≤ 0.05 after the Student Neuman Keuls test and one-way analysis of
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variance; scale bar in A and B1–3 = 100 μm, and in A and B4–6 = 100 μm). Arrows indicate
positions of blood vessels, and the arrowhead indicates a typical ED-1-expressing
macrophage. (C) Left panel shows counts of macrophages in a 0.2-mm2 area within the
injured brain in the sham, 1B7 control, and anti-CD11d-treated groups at 72 h (n = 4/group;
analysis of variance [ANOVA]: F2,9 = 61.34, p < 0.001). Right panel shows counts of
macrophages at 4 weeks after traumatic brain injury (TBI) (n = 7, 6, and 6, respectively;
ANOVA: F2,16 = 7.04, p = 0.006). (D) Macrophage protein identified by Western blotting in
cord homogenates expressed as mean values ± standard error, with a representative
autoradiogram shown above each set of histograms. Macrophage protein is shown at 24 h,
72 h, and 4 weeks in the sham-injured, 1B7 control, and anti-CD11d groups (n = 5/group;
ANOVA: 24 h, F2,12 = 7.15, p = 0.009; 72 h, F2,12 = 17.44, p < 0.001; 4 weeks, F2,12 =
15.95, p < 0.001; A.U., arbitrary units). Color image is available online at
www.liebertonline.com/neu
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FIG. 4.

Lipid peroxidation is reduced by the anti-CD11d treatment. TBARS concentrations at 24 h
after TBI in the sham-injured (n = 6), 1B7 control, and anti-CD11d (n = 7 each) groups; at
72 h in these groups (n = 7, 7, and 8, respectively), and at 4 weeks (n = 5, 6, and 5,
respectively; analysis of variance [ANOVA]: 24 h, F2,17 = 4.68, p = 0.024; 72 h, F2,19 =
5.10, p = 0.017; 4 weeks, F2,13 = 5.3, p = 0.021; ANOVA, analysis of variance; TBI,
traumatic brain injury; TBARS, thiobarbituric acid reactive substances; *significantly
different from sham animals, and #significantly different from the 1B7 control group, p ≤
0.05 after the Student Neuman Keuls test and one-way ANOVA).
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FIG. 5.
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Astrogliosis assessed by the expression of glial fibrillary acidic protein (GFAP) in the
injured brain is reduced by the anti-CD11d treatment. (A) GFAP, identified by Western
blotting in cord homogenates, is shown at 24 h, 72 h, and 4 weeks, in the sham-injured, 1B7
control, and anti-CD11d groups (n = 5/group; analysis of variance [ANOVA]: 24 h, F2,12 =
35.75, p < 0.001; 72 h, F2,12 = 15.38, p < 0.001; 4 weeks, F2,12 = 22.27, p < 0.001). (B)
Shown are photomicrographs of brain sections at the location of the fluid percussion injury
immunostained by an antibody to GFAP. Boxed areas in panels 1–3 are shown at higher
power in panels 4–6 (scale bars = 100 μm in A1–3 and in A4–6). Arrowheads indicate
examples of reactive astrocytes. Note the increased intensity of anti-GFAP staining and the
presence of overlapping, hypertrophic GFAP-positive processes in the sections from 1B7
controls (panels 2 and 5), compared to anti-CD11d treated rats (panels 3 and 6;
*significantly different from sham animals, and #significantly different from the 1B7 control
group, p ≤ 0.05 after the Student Neuman Keuls test and one-way ANOVA; A.U., arbitrary
units). Color image is available online at www.liebertonline.com/neu
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FIG. 6.
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The increase in amyloid precursor protein (APP) expression in the injured brain is reduced
by the anti-CD11d treatment. (A) APP, identified by Western blotting in brain homogenates,
is shown at 24 h, 72 h, and 4 weeks, in the sham-injured, 1B7 control, and anti-CD11d
groups (n = 5/group; analysis of variance [ANOVA]: 24 h, F2,12 = 10.46, p = 0.002; 72 h,
F2,12 = 22.11, p < 0.001; 4 weeks, F2,12 = 9.04, p = 0.004). (B) Photomicrographs of the
cortex centered on the lesion epicenter (or a comparable position in sham-injured rats)
immunostained by an antibody to APP. Boxed areas in panels 1–3 are shown at high power
in panels 4–6 (scale bars = 100 μm in A1–3 and A4–6). Arrowheads indicate APP-positive
aggregates (*significantly different from sham animals, and #significantly different from the
1B7 control group, p ≤ 0.05 after the Student Neuman Keuls test and one-way ANOVA;
A.U., arbitrary units). Color image is available online at www.liebertonline.com/neu
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FIG. 7.

Expression of neuronal nuclear antigen (NeuN) in the injured brain. NeuN, identified by
Western blotting in brain homogenates, is shown at 24 h, 72 h, and 4 weeks in the shaminjured, 1B7 control, and anti-CD11d groups (n = 5/group; analysis of variance [ANOVA]:
24 h, F2,12 = 10.42, p = 0.002; 72 h, F2,12 = 28.96, p < 0.001; 4 weeks, F2,12 = 12.52, p =
0.001; *significantly different from sham animals, and #significantly different from the 1B7
control group, p ≤ 0.05 after the Student Neuman Keuls test and one-way ANOVA; A.U.,
arbitrary units).
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FIG. 8.

Counts of neurons in the hippocampus identified by neuronal nuclear antigen (NeuN). (A)
Photomicrographs of sections of the hippocampus within the region of the FPI
immunostained by an antibody to NeuN. The sections from the sham-injured, 1B7 control,
and anti-CD11d groups are shown at low power in panels 1–3, and boxed areas are shown at
high power in panels 4–6 (scale bars = 100 μm in A1-3 and A4-6). (B) Counts of neurons in
a 0.33-mm2 area of interest (boxed areas in the images) within the hippocampus. Neuron
counts are shown at 24h in the sham-injured, 1B7 control, and anti-CD11d groups (n = 4/
group) at 24h, 72h (n = 5/group), and 4 weeks (n=9, 8, and 7, respectively; analysis of
variance [ANOVA]: 24h, F2,9 = 0.06, p = 0.943; 72h, F2,12 = 0.15, p = 0.865; 4 weeks,
F2,21=4.35, p = 0.026; *Significantly different from sham animals, and #significantly
different from the 1B7 control group, p≤0.05 after the Student Neuman Keuls test and oneway ANVOVA). Color image is available online at www.liebertonline.com/neu

CIHR Author Manuscript
J Neurotrauma. Author manuscript; available in PMC 2016 May 03.

Bao et al.

Page 29

CIHR Author Manuscript
CIHR Author Manuscript
FIG. 9.

CIHR Author Manuscript

The anti-CD11d treatment improved spatial cognition in the short recovery (SR) group as
assessed by water maze testing. (A) Graph of search times for the acquisition task in the SR
analysis for sham-injured rats (SHAM-SR, open triangles), 1B7-treated rats (1B7-SR, gray
squares), and anti-CD11d-treated rats (CD11d-SR, solid black circles). Each block plotted
on the x-axis represents the average of results of 2 of the 10 trials (n = 12 rats/group; *antiCD11d-SR and 1B7-SR groups had significantly longer search times than the sham-SR
group). (B) Percent of direct and circle swims in the acquisition task in the SR analysis for
the three groups of rats. Histogram bars represent means of data during 10 water maze trials
(*1B7-SR rats had significantly fewer direct and circle swims than the sham-SR rats;
analysis of variance [ANOVA]: F2,36 = 5.616, p<0.01). (C) Swim speeds during these trials
of acquisition testing did not differ between the three groups. (D) Search times for the
reversal task in the SR analysis of reversal training (format and number of rats as in A; #the
anti CD11d-SR group had significantly shorter search times compared to the 1B7-SR group,
but did not differ from the sham-SR group; *the 1B7-SR group had significantly longer
search times than the sham-SR group). (E) Direct and circle swims in the reversal task for
J Neurotrauma. Author manuscript; available in PMC 2016 May 03.

Bao et al.

Page 30

CIHR Author Manuscript

the three groups of SR rats (#significantly more direct and circle swims than the 1B7-SR
group; *different from sham-SR; ANOVA: F2,36 = 4.223, p<0.05). The anti-CD11d-SR
group did not differ from the sham-SR group. (F) Swim speeds during these trials of
acquisition training did not differ between the three groups.

CIHR Author Manuscript
CIHR Author Manuscript
J Neurotrauma. Author manuscript; available in PMC 2016 May 03.

Bao et al.

Page 31

CIHR Author Manuscript
CIHR Author Manuscript
FIG. 10.
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Anti-CD11d treatment improved spatial cognition in the long recovery (LR) water maze. (A
and D) No differences in search time in the acquisition or reversal tasks were found among
the sham-injured rats (SHAM-SR, open triangles), 1B7-treated rats (1B7-SR, gray squares),
and anti-CD11d-treated rats (CD11d-SR, solid black circles; n = 7 rats/group) tested 4
weeks post-injury. (B and E) Percentages of direct and circle swims in the study groups
during acquisition and reversal training. Histogram bars represent means of data collected
during the 10 water maze trials (*significantly different from sham-LR rats; F2,41 =4.346,
p<0.05). The CD11d-LR group was no different from the sham-LR group. (C and F) Swim
speeds during acquisition and reversal training were no different between the groups.
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FIG. 11.
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The anti-CD11d treatment improved long recovery (LR) beam task performance. (A)
Number of slips and falls during the beam task in the sham-short recovery (SHAM-SR),
1B7-SR, and CD11d-SR groups of rats (n = 12/group). Histogram bars represent means of
data collected during the 10 beam task trials (*significantly different from the sham-SR
group; F2,36=3.748, p<0.05). The CD11d-SR group did not differ from sham-SR group. (B)
Number of slips and falls in the LR groups (n =7/group; #significantly different from the
1B7-LR group; *different from the sham-LR group; F2,41 = 4.526, p<0.05). The CD11d-LR
group did not differ from the sham-LR group.
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FIG. 12.
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Anti-CD11d treatment reduces anxiety in long recovery (LR) testing. Time spent in the open
arm of the maze (reciprocally related to anxiety; A), and number of entries into the closed
arm (B), by the short recovery (SR) sham-injured (SHAM-SR, n =24), 1B7 (1B7-SR, n =
24), and anti-CD11d (CD11d-SR, n = 25) groups of rats. Histogram bars represent time or
entries accrued during 5 min of free exploration. No significant differences were detected
among the groups at this time. Time spent in the open arm of the maze (C), and number of
closed arm entries (D), by the LR groups of rats (n = 14 rats/group; #significantly different
from the 1B7-LR group; *significantly different from the sham-LR group; F2,41 =3.925,
p<0.05). The CD11d-LR group did not differ from the sham-LR group in time spent in the
open arm. The three LR groups did not differ from each other in the number of entries into
the closed arm (SHAM-LR, sham-long recovery; 1B7-LR, 1B7-long recovery; CD11d-LR,
CD11d-long recovery).
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Numbers of Rats Used in Each Part of the Study
MPO and MDA assays

a

24 h

72 h

4 weeks

Sham-injured

6

7

5

TBI 1B7 control

7

8

6

TBI anti-CD11d

7

7

5

Western blotsa

24 h

72 h

4 weeks

Sham-injured

5

5

5

TBI 1B7 control

5

5

5

TBI anti-CD11d

5

5

5

Neutrophil, macrophage (ED-1), GFAP, APP, and NeuN blots.

Tissues used in the assays were sampled from 6 sham, 7 1B7, and 7 anti-CD11d rats at 24 h, from 7 sham, 8 1B7, and 7 anti-CD11d rats at 72 h,
and from 5 sham, 6 1B7, and 5 anti-CD11d rats at 4 weeks.
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GFAP, glial fibrillary acidic protein; APP, amyloid precursor protein; NeuN, neuronal nuclear antigen; TBI, traumatic brain injury; MPO
myeloperoxidase; MDA, malondialdehyde.
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Neurological and Immunohistochemical Results
Neutrophil

Macrophage

Macrophage

Immune cell counts

24 h

72 h

4 weeks

Sham-injured

4

4

7

TBI 1B7 control

4

4

6

TBI anti-CD11d

4

4

6

24 h

72 h

4 weeks

Sham-injured

5

5

9

TBI 1B7 control

5

5

9

TBI anti-CD11d

5

5

9

24 h

72 h

4 weeks

Sham-injured

4

5

9

TBI 1B7 control

4

5

8

TBI anti-CD11d

4

5

7

Histochemical and immunohistochemical staining

Hippocampal neuron counts
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Short recovery (24 h)a

Long recovery (4 weeks)b

Sham-injured

24

14

TBI 1B7 control

24

14

TBI anti-CD11d

25

14

Elevated-plus maze task

Water maze and beam task

Short recovery (24 h)

Long recovery (4 weeks)

Sham-injured

12

7

TBI 1B7 control

12

7

TBI anti-CD11d

12

7

Neurological measures
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Treatment group

Apnea (sec)

Unconsciousness (sec)

Self-righting (sec)

CD11d

7.94 ± 0.84a

98.05 ± 12.54a

685.77 ± 202.03a

1B7 control

7.64 ± 0.54a

98.24 ± 12.45a

694.84 ± 183.27a

0±0

0±0

272.84 ± 17.64

Sham-injured

Tissues used in these analyses were sampled from 5 rats per group at 24 h and at 72 h after injury and from 9 rats per group at 4 weeks after injury.

a
12 of these rats were not tested further as they were perfused at 24 h or 72 h after injury and used for assays and counts.
b

7 rats were not tested further; these 7 rats and the 7 rats that underwent further testing were perfused for assays, cell counting, and histochemistry
at 4 weeks.

a

Different horn sham–self-righting (p < 0.001).

The CD11d- and 1B7 mAb-treated groups displayed significantly longer apnea, unconsciousness, and self-righting reflex times than the shaminjured group.
TBI, traumatic brain injury.
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